<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170883</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01451</org_study_id>
    <nct_id>NCT02170883</nct_id>
  </id_info>
  <brief_title>EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS</brief_title>
  <official_title>EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WelTel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Pharmacists of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 8% and 12% of Canadians suffer from asthma. Although there are effective and&#xD;
      inexpensive treatments, adherence to asthma treatment is amongst the lowest for all chronic&#xD;
      diseases.The purpose of this study is to determine whether enhancing the role of community&#xD;
      pharmacists in asthma management using interactive short messaging service (SMS) with asthma&#xD;
      patients is a cost-effective model that will improve adherence to inhaled corticosteroid&#xD;
      medications compared to usual care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to inhaled corticosteroid medication</measure>
    <time_frame>12 months</time_frame>
    <description>Adherence assessed by medication possession ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>Baseline</time_frame>
    <description>Asthma control assessed by the Asthma Control Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>6 months</time_frame>
    <description>Asthma control assessed by the Asthma Control Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma control assessed by the Asthma Control Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by the Asthma Quality of Life Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Quality of life measured by the Asthma Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by the Asthma Quality of Life Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of life measured by the Asthma Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by the Asthma Quality of Life Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life measured by the Asthma Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource utilization</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma-related hospital admissions and emergency department visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of reliever medication for acute asthma attacks</measure>
    <time_frame>12 months</time_frame>
    <description>Use of reliever medication for acute asthma attacks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Interactive SMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement &quot;I follow my asthma medication plan&quot; and pharmacist follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacist conducted patient education, counseling and action-plan</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interactive SMS</intervention_name>
    <arm_group_label>Interactive SMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  individuals who fill a (incident or prevalent) prescription for inhaled&#xD;
             corticosteroids (either monotherapy or in combination inhaler with long-acting&#xD;
             beta-agonists) who have been diagnosed by a doctor as having asthma&#xD;
&#xD;
          -  possessing a cell-phone with ability to send/receive text messages&#xD;
&#xD;
          -  residing in British Columbia (BC), Canada and planning to reside in BC for the next 12&#xD;
             months&#xD;
&#xD;
          -  registered with the medical services plan (MSP, the provincial insure of&#xD;
             medically-required services) in the past 12 months, and planning to remain registered&#xD;
             for the next 12 months&#xD;
&#xD;
          -  designated pharmacy being the main drugstore for patient&#xD;
&#xD;
          -  not participating in another interventional study&#xD;
&#xD;
          -  consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to communicate in English&#xD;
&#xD;
          -  Under 14 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary De Vera, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UBC</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Mary De Vera</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>mHealth</keyword>
  <keyword>cluster randomized controlled trial</keyword>
  <keyword>pharmacy practice</keyword>
  <keyword>pharmacist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

